VivoSeq
Oncology

Serous Carcinoma

1

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Serous Carcinoma is an early-stage landscape with 1 program across 3 companies. The most active players are Boehringer Ingelheim, AstraZeneca, K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

83/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2AstraZeneca logo

AstraZeneca

0 programs

PreclinicalK

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Afatinib

Boehringer Ingelheim

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

10

clinical trials

Completed5 · 50%
Recruiting3 · 30%
Active, not recruiting1 · 10%
Terminated1 · 10%

Clinical Trials

Trial Activity

10 trials

Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Recruiting·—·Phase 2·NCT06369155·25 enrolled
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Recruiting·SShandong University·Phase 2·NCT04716686·83 enrolled
A Phase II Evaluation of Afatanib, an Irreversible Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Tyrosine Kinase Inhibitor, in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Recruiting·YYale University·Phase 2·NCT02491099·50 enrolled
Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma
Active, not recruiting·—·Phase 2·NCT05870761·8 enrolled
A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT04590248·109 enrolled
Papillary Serous Carcinoma of the Endometrium
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00515073·30 enrolled
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
Completed·NNorthwell Health·Phase 2·NCT04080284·22 enrolled
Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
Completed·—·Phase 2/3·NCT03285802·1 enrolled
A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
Completed·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 2·NCT04814108·92 enrolled
Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00506779·17 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)